Podcast: ART in Older PWH
Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

Released: December 21, 2021

Expiration: December 20, 2022

Jonathan Appelbaum
Jonathan Appelbaum, MD, FACP, AAHIVS
Jens D. Lundgren
Jens D. Lundgren, MD, DMSc

Activity

Progress
1
Course Completed

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:

  • DHHS, EACS, IAS, and WHO recommendations for first-line ART
  • Virologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National Survey
  • Polypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairment
  • Cardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ART